Please wait a minute...
浙江大学学报（医学版）
浙江大学学报（医学版）  2020, Vol. 49 Issue (4): 419-424    DOI: 10.3785/j.issn.1008-9292.2020.08.17
专题报道     
发作性睡病的药物治疗进展
徐清霖1,2(),楼国东3,王甜甜3,张力三1,2,*()
1. 浙江大学医学院附属邵逸夫医院神经内科, 浙江 杭州 310016
2. 浙江大学医学院附属邵逸夫医院睡眠中心, 浙江 杭州 310016
3. 浙江大学医学院附属邵逸夫医院药学部, 浙江 杭州 310016
Advances in treatment of narcolepsy
XU Qinglin1,2(),LOU Guodong3,WANG Tiantian3,ZHANG Lisan1,2,*()
1. Department of Neurology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China
2. Center for Sleep Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China
3. Department of Pharmacy, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China
 全文: PDF(1066 KB)   HTML( 19 )
摘要：

发作性睡病是致残性白天睡眠增多的最常见原因之一，其治疗旨在减少白天睡眠增多和猝倒，改善夜间睡眠紊乱、睡眠瘫痪及与睡眠有关的幻觉。2019年，组胺H3受体拮抗剂替洛利生（Pitolisant）和多巴胺及去甲肾上腺素再摄取抑制剂索利氨酯（Solriamfetol）分别在欧盟和美国上市，前者具有促醒和抗猝倒作用，后者也有促醒作用，且戒断症状和滥用的发生率更低。目前，控释型羟丁酸钠（FT218）、低钠型羟丁酸盐（JZP-258）、选择性去甲肾上腺素再摄取抑制剂（瑞波西汀，又称AXS-12）以及莫达非尼联合氟卡尼制剂（THN102）等药物仍在开发和测试中，均可作为治疗发作性睡病相关白天睡眠增多和猝倒的潜在药物。本文重点介绍这些最近研发的发作性睡病治疗药物。
关键词： 发作性睡病;  替洛利生;  索利氨酯;  羟丁酸钠;  制剂;  副作用;  综述    
Abstract:

Narcolepsy is the most common cause of excessive daytime sleepiness (EDS) following obstructive sleep apnea. Its treatment aims to reduce EDS and cataplexy, improve nighttime sleep disturbance, sleep paralysis and sleep-related hallucinations. Pitolisant (a histamine H3 receptor antagonist) and solriamfetol (a norepinephrine reuptake inhibitor) have recently been approved effective for narcolepsy in the United States and the European Union. Pitolisant has proved to be effective for both EDS and cataplexy. Besides being effective on EDS, solriamfetol seems to have advantages in abuse potential and withdrawal syndrome. As potential treatments for EDS and cataplexy associated with narcolepsy, several new drugs are being developed and tested. These new drugs include new hydroxybutyrate preparations (controlled release sodium hydroxybutyrate FT218, low sodium hydroxybutyrate JZP-258), selective norepinephrine reuptake inhibitor (AXS-12), and modafinil combined with astroglial junction protein inhibitor (THN102). This paper reviews the recently approved drugs and potential treatments for narcolepsy.
Key words: Narcolepsy    Pitolisant    Solriamfetol    Sodium oxybate    Preparation    Side effect    Review
收稿日期: 2020-06-30 出版日期: 2020-09-27
:  R741  
基金资助: 浙江省医药卫生科技计划(2020383055, 2020KY164)
通讯作者: 张力三     E-mail: rainkei@zju.edu.cn;zls09@zju.edu.cn
作者简介: 徐清霖(1989-), 女, 硕士, 住院医师, 主要从事神经病学和睡眠医学研究; E-mail:rainkei@zju.edu.cn; https://orcid.org/0000-0003-2620-1671
服务　　
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章　　
徐清霖
楼国东
王甜甜
张力三

引用本文:

徐清霖,楼国东,王甜甜,张力三. 发作性睡病的药物治疗进展[J]. 浙江大学学报（医学版）, 2020, 49(4): 419-424.

XU Qinglin,LOU Guodong,WANG Tiantian,ZHANG Lisan. Advances in treatment of narcolepsy. J Zhejiang Univ (Med Sci), 2020, 49(4): 419-424.

链接本文:

http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2020.08.17    或    http://www.zjujournals.com/med/CN/Y2020/V49/I4/419

1 BASSETTI C , ADAMANTIDIS A , BURDAKOV D et al. Narcolepsy-clinical spectrum, aetiopathophysiology, diagnosis and treatment[J]. Nat Rev Neurol, 2019, 15 (9): 519- 539
doi: 10.1038/s41582-019-0226-9
2 HUBLIN C , PARTINEN M , KAPRIO J et al. Epidemiology of narcolepsy[J]. Sleep, 1994, 17 (8 Suppl): S7- 12
doi: 10.1093/sleep/17.suppl_8.s7
3 HEIER M S , EVSIUKOVA T , WILSON J et al. Prevalence of narcolepsy with cataplexy in Norway[J]. Acta Neurol Scand, 2009, 120 (4): 276- 280
doi: 10.1111/j.1600-0404.2009.01166.x
4 TIÓ E, GAIG C, GINER-SORIANO M, et al. The prevalence of narcolepsy in Catalunya (Spain)[J/OL]. J Sleep Res, 2018, 27(5): e12640. DOI: 10.1111/jsr.12640.
5 中华医学会神经病学分会, 中华医学会神经病学分会睡眠障碍学组, 解放军医学科学技术委员会神经内科专业委员会睡眠障碍学组 . 中国发作性睡病诊断与治疗指南[J]. 中华神经科杂志, 2015, 48 (6): 445- 452
Chinese Society of Neurology , Sleep Disorders Group of Chinese Society of Neurology , Sleep Disorders Group of Neurology Commission of Military Medical-Scientific Commission . Chinses guideline for narcolepsy diagnosis and treatment[J]. Chinese Journal of Neurology, 2015, 48 (6): 445- 452
doi: 10.3760/cma.j.issn.1006-7876.2015.06.003
6 BLACK J , REAVEN N L , FUNK S E et al. Medical comorbidity in narcolepsy:findings from the Burden of Narcolepsy Disease (BOND) study[J]. Sleep Med, 2017, 33 13- 18
doi: 10.1016/j.sleep.2016.04.004
7 BLACK J , REAVEN N L , FUNK S E et al. The Burden of Narcolepsy Disease (BOND) study:health-care utilization and cost findings[J]. Sleep Med, 2014, 15 (5): 522- 529
doi: 10.1016/j.sleep.2014.02.001
8 SCHNEIDER L , MIGNOT E . Diagnosis and management of narcolepsy[J]. Semin Neurol, 2017, 37 (4): 446- 460
doi: 10.1055/s-0037-1605554
9 SATEIA M J . International Classification of sleep disorders-third edition[J]. Chest, 2014, 146 (5): 1387- 1394
doi: 10.1378/chest.14-0970
10 BROUGHTON R J , FLEMING J A , GEORGE C F et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy[J]. Neurology, 1997, 49 (2): 444- 451
doi: 10.1212/wnl.49.2.444
11 MIGNOT E J . A practical guide to the therapy of narcolepsy and hypersomnia syndromes[J]. Neurotherapeutics, 2012, 9 (4): 739- 752
doi: 10.1007/s13311-012-0150-9
12 ARAN A , EINEN M , LIN L et al. Clinical and therapeutic aspects of childhood narcolepsy-cataplexy:a retrospective study of 51 children[J]. Sleep, 2010, 33 (11): 1457- 1464
doi: 10.1093/sleep/33.11.1457
13 GUILLEMINAULT C , RAYNAL D , TAKAHASHI S et al. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride[J]. Acta Neurol Scand, 1976, 54 (1): 71- 87
doi: 10.1111/j.1600-0404.1976.tb07621.x
14 JIN L , SHI L , ZHANG Y et al. Antidepressants for the treatment of narcolepsy:A prospective study of 148 patients in northern China[J]. J Clin Neurosci, 2019, 63 27- 31
doi: 10.1016/j.jocn.2019.02.014
15 MAYER G , PLAZZI G , IRANZO á et al. Long-term compliance, safety, and tolerability of sodium oxybate treatment in patients with narcolepsy type 1:a postauthorization, noninterventional surveillance study[J]. Sleep, 2018, 41 (9):
doi: 10.1093/sleep/zsy128
16 DAUVILLIERS Y , BASSETTI C , LAMMERS G J et al. Pitolisant versus placebo or modafinil in patients with narcolepsy:a double-blind, randomised trial[J]. Lancet Neurol, 2013, 12 (11): 1068- 1075
doi: 10.1016/S1474-4422(13)70225-4
17 KOLLB-SIELECKA M , DEMOLIS P , EMMERICH J et al. The European Medicines Agency review of pitolisant for treatment of narcolepsy:summary of the scientific assessment by the Committee for Medicinal Products for Human Use[J]. Sleep Med, 2017, 33 125- 129
doi: 10.1016/j.sleep.2017.01.002
18 SZAKACS Z , DAUVILLIERS Y , MIKHAYLOV V et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy:a randomised, double-blind, placebo-controlled trial[J]. Lancet Neurol, 2017, 16 (3): 200- 207
doi: 10.1016/S1474-4422(16)30333-7
19 DAUVILLIERS Y , ARNULF I , SZAKACS Z et al. Long-term use of pitolisant to treat patients with narcolepsy:Harmony Ⅲ Study[J]. Sleep, 2019, 42 (11):
doi: 10.1093/sleep/zsz174
20 THORPY M J . Recently approved and upcoming treatments for narcolepsy[J]. CNS Drugs, 2020, 34 (1): 9- 27
doi: 10.1007/s40263-019-00689-1
21 THORPY M J , SHAPIRO C , MAYER G et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy[J]. Ann Neurol, 2019, 85 (3): 359- 370
doi: 10.1002/ana.25423
22 MALHOTRA A , SHAPIRO C , PEPIN J L et al. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea[J]. Sleep, 2020, 43 (2):
doi: 10.1093/sleep/zsz220
23 ABAD V C , GUILLEMINAULT C . New developments in the management of narcolepsy[J]. Nat Sci Sleep, 2017, 9 39- 57
doi: 10.2147/NSS.S103467
24 BARKER E C , FLYGARE J , PARUTHI S et al. Living with narcolepsy:current management strategies, future prospects, and overlooked real-life concerns[J]. Nat Sci Sleep, 2020, 12 453- 466
doi: 10.2147/NSS.S162762
25 BOGAN R, THORPY M, DAUVILLIERS Y, et al. Efficacy and safety of JZP-258 in a phase 3 double-blind, placebo-controlled, randomised-withdrawl study in adults with narcolepsy with cataplexy[R]. Vancouver: Biennial World Sleep Congress, 2019.
26 HAJóS M , FLEISHAKER J C , FILIPIAK-REISNER J K et al. The selective norepinephrine reuptake inhibitor antidepressant reboxetine:pharmacological and clinical profile[J]. CNS Drug Rev, 2004, 10 (1): 23- 44
doi: 10.1111/j.1527-3458.2004.tb00002.x
27 SCHMIDT C , LEIBIGER J , FENDT M . The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram[J]. Behav Brain Res, 2016, 308 205- 210
doi: 10.1016/j.bbr.2016.04.033
28 LARROSA O , DE LA LLAVE Y , BARIO S et al. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy:a pilot study[J]. Sleep, 2001, 24 (3): 282- 285
doi: 10.1093/sleep/24.3.282
29 FDA Grants Axsome Therapeutics' AXS-12 Breakthrough Therapy Designation for Treatment of Narcolepsy[N/OL]. (2020-08-05)[2020-08-10]. https://www.spjnews.com/2020/08/05/fda-grants-axsome-therapeutics-axs-12-breakthrough-therapy-designation-for-treatment-of-narcolepsy/.
30 BOIVIN D B , MONTPLAISIR J , PETIT D et al. Effects of modafinil on symptomatology of human narcolepsy[J]. Clin Neuropharmacol, 1993, 16 (1): 46- 53
doi: 10.1097/00002826-199302000-00005
31 DUCHêNE A , PERIER M , ZHAO Y et al. Impact of astroglial connexins on modafinil pharmacological properties[J]. Sleep, 2016, 39 (6): 1283- 1292
doi: 10.5665/sleep.5854
32 National Institutes of Health. Safety and efficacy of THN102 on sleepiness in narcoleptic patients[EB/OL]. (2016-07-01)[2019-04-26]. https://clinicaltrials.gov/ct2/show/NCT02821715.
33 BONVALET M , OLLILA H M , AMBATI A et al. Autoimmunity in narcolepsy[J]. Curr Opin Pulm Med, 2017, 23 (6): 522- 529
doi: 10.1097/MCP.0000000000000426
34 YUKITAKE H , FUJIMOTO T , ISHIKAWA T et al. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice[J]. Pharmacol Biochem Behav, 2019, 187 172794
doi: 10.1016/j.pbb.2019.172794
[1] 蒋沛然, 王志萍. 模式生物神经轴突再生的研究进展[J]. 浙江大学学报（医学版）, 2020, 49(4): 500-507.
[2] 孔元梅,陈虹,梁黎,郑卯昵,方燕兰,王春林. 芳香化酶抑制剂联合生长激素治疗青春期身材矮小症男性患儿的临床研究[J]. 浙江大学学报（医学版）, 2020, 49(3): 283-290.
[3] 王春林,梁黎. 第三代非甾体类芳香化酶抑制剂在儿科内分泌临床应用的再认识[J]. 浙江大学学报（医学版）, 2020, 49(3): 275-282.
[4] 于冰青,聂敏,伍学焱,茅江峰,王曦,马婉璐,季文,黄奇彬,张睿. 来曲唑有效提高性发育异常男性患儿的睾酮水平[J]. 浙江大学学报（医学版）, 2020, 49(3): 297-301.
[5] 徐德,陆文丽,王雪晴,王俊祺,谢轶雯,董治亚,王伟. 来曲唑治疗纤维性骨营养不良综合征女性患儿外周性性早熟疗效观察[J]. 浙江大学学报（医学版）, 2020, 49(3): 291-296.
[6] 王倩,张书乐,马雪,李桂梅,王增敏,王凤雪. 来曲唑对21-羟化酶缺乏型先天性肾上腺皮质增生症患儿生长发育的影响[J]. 浙江大学学报（医学版）, 2020, 49(3): 302-307.
[7] 李燕虹,杜敏联,马华梅,陈秋莉,陈红珊,张军. 来曲唑改善青春期特发性身材矮小症男性患儿成年身高的疗效评价[J]. 浙江大学学报（医学版）, 2020, 49(3): 308-314.
[8] 王燚锋, 王志萍. 内源性信号通路在神经元轴突再生中的功能和机制研究[J]. 浙江大学学报（医学版）, 2020, 49(1): 82-89.
[9] 俞卿, 熊秀芳, 孙毅. 靶向Cullin-RING E3泛素连接酶的抗肿瘤策略及相关药物研发进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 1-19.
[10] 段玲艳,尹香菊,孟红恩,方学贤,闵军霞,王福俤. 铁稳态代谢表观遗传调控机制的研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 58-70.
[11] 李艾,张添源,高建青. 间充质干细胞的肿瘤归巢特性及其肿瘤靶向治疗应用研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 20-34.
[12] 黄耀凭,杨凤,周天华,谢珊珊. Hippo信号通路及其在消化系统肿瘤中的作用研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 35-43.
[13] 钟文,楼燕,邱宸阳,李栋林,张鸿坤. 髂静脉支架植入术后药物治疗策略研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 131-136.
[14] 徐亦鸣,应可净. 中性粒细胞胞外诱捕网与肿瘤相关研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 107-112.
[15] 刘晓晓,郭莉琼,梁成. 抗N-甲基-D-天冬氨酸受体脑炎患者脑电图特点的研究进展[J]. 浙江大学学报（医学版）, 2020, 49(1): 118-123.